We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.
- Authors
Feng, Hwa‐Ping; Guo, Zifang; Caro, Luzelena; Marshall, William L.; Liu, Fang; Panebianco, Deborah; Vaddady, Pavan; Reitmann, Christina; Jumes, Patricia; Wolford, Dennis; Fraser, Iain; Valesky, Robert; Martinho, Monika; Butterton, Joan R.; Iwamoto, Marian; Webster, Lynn; Yeh, Wendy W.
- Abstract
We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK‐8742‐P010 and MK‐5172‐P030) in non‐hepatitis C virus (HCV)‐infected participants on methadone maintenance therapy. Coadministration of EBR or GZR with methadone had no clinically meaningful effect on EBR, GZR, or methadone pharmacokinetics. The geometric mean ratios (GMRs) for R‐ and S‐methadone AUC0‐24 were 1.03 (90% confidence interval (CI), 0.92–1.15) and 1.09 (90% CI, 0.94–1.26) in the presence/absence of EBR; and 1.09 (90% CI, 1.02–1.17) and 1.23 (90% CI, 1.12–1.35) in the presence/absence of GZR. The GMRs for EBR and GZR AUC0‐24 in participants receiving methadone relative to a healthy historical cohort not receiving methadone were 1.20 (90% CI, 0.94–1.53) and 1.03 (90% CI, 0.76–1.41), respectively. These results indicate that no dose adjustment is required for individuals with HCV infection receiving stable methadone therapy and the EBR/GZR fixed‐dose regimen.
- Subjects
METHADONE treatment programs; PHARMACOKINETICS; CLINICAL trials; HEPATITIS C; DRUG administration
- Publication
CTS: Clinical & Translational Science, 2018, Vol 11, Issue 6, p553
- ISSN
1752-8054
- Publication type
Article
- DOI
10.1111/cts.12564